|Bid||0.0000 x 1200|
|Ask||0.0000 x 1800|
|Day's Range||2.9950 - 3.1208|
|52 Week Range||2.7900 - 4.9500|
|Beta (3Y Monthly)||1.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 6, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.17|
ChromaDex Corp. (CDXC) issued the following statement. Through discovery, we learned of egregious behavior by Elysium related to the theft of trade secrets and confidential information including text messages revealing unethical conduct and a stated intention to “destroy” ChromaDex. In his order, the judge seeks additional information about how ChromaDex was damaged by the theft, and we look forward to answering his questions.
Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa, receives a research grant from the Bill & Melinda Gates Foundation to study the effects of NAD-boosting supplements on the production of bioactive factors in milk and the effect of the supplements on brain development in animals. Dr. Brenner explained that his previous research indicated that a new mother’s body does everything in its power to provide for the needs of her offspring: mobilizing her own protein, fat and carbohydrate to make milk, mobilizing her own NAD precursors for the offspring, and producing bioactive factors important for the brain and physical development of her offspring. The new mother’s body does so much that she experiences postpartum as a metabolic stress.
LOS ANGELES, Sept. 26, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present.
BIRMINGHAM, Ala., Sept. 10, 2019 /PRNewswire/ -- Yuva Biosciences, Inc., an anti-aging company developing cosmeceuticals as well as pharmaceuticals targeted at aging-associated hair loss, wrinkled skin, and reduced energy, today announced that Aubrey de Grey, Ph.D. and Frank L. Jaksch, Jr. have joined the Company's Advisory Board. "We are thrilled to have two of the pioneering thinkers in the industry, Aubrey de Grey and Frank Jaksch, join our Advisory Board," said Greg Schmergel, Chairman at Yuva Biosciences.
ChromaDex Corp. (CDXC) announced today that it has entered into a securities purchase agreement for the sale of $7.0 million of its common stock in a private placement. The private placement was led by new strategic investors. The private placement is expected to close on or about August 15, 2019, subject to the satisfaction of customary closing conditions.
ChromaDex (CDXC) delivered earnings and revenue surprises of 15.38% and 2.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
ChromaDex Corp. (CDXC) today announced that the European Food Safety Authority (EFSA) has issued a positive opinion on Nicotinamide Riboside (NR) as a novel food ingredient for use in a food supplement at a daily serving of 300mg for the healthy adult population, a critical step in the EU regulatory approval process. “Safety is paramount for ChromaDex and this positive opinion from EFSA underscores our depth of science, and is the latest in a consistently positive series of reviews of NR by authoritative bodies,” said ChromaDex CEO Rob Fried.
Second Quarter 2019 Highlights vs. Second Quarter 2018 Strong growth in net sales to $11.1 million, significantly higher gross margins, and improved marketing.
ChromaDex Corp. (CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today three strategic hires to its executive team. Joining the company are Megan Jordan as Chief Communications Officer & Senior Vice President of Global Corporate Affairs, Dr. Andrew Shao as Vice President of Scientific & Regulatory Affairs, and Alberto Bottene as Senior Vice President of Sales and Business Development.
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LOS ANGELES, July 31, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., August 7, 2019 at 4:30 p.m. Eastern time to discuss its.
ChromaDex Corp. (CDXC) announced today its flagship consumer product, Tru Niagen® (nicotinamide riboside) is now available in all seven Whole Foods Market locations across Ontario, in addition to select Pure Pharmacy locations, Fullscript Canada, and online. Tru Niagen joins Whole Foods as the store’s newest product in the energy category based on its strong clinical results and scientific research.
ChromaDex Corp. (CDXC) announced today it has appointed Brunie H. Felding, Ph.D., Associate Professor, Department of Molecular Medicine, Scripps Research Institute, California Campus, to the Scientific Advisory Board (SAB). The group of scientists Dr. Felding leads at Scripps has conducted research that has shown that increasing NAD+ with the B3 vitamin nicotinamide prevented breast cancer development in mice.
ChromaDex Corp (NASDAQ: CDXC ) announced the results of its latest clinical study were published in the journal Scientific Reports. The study further validates the safety and efficacy of ChromaDex’s proprietary ...
ChromaDex Corp. (CDXC) announced today that the results of its latest clinical study were published Friday in the journal Scientific Reports. The largest trial of nicotinamide riboside (NR) published to date, the new study further validates the safety and efficacy of ChromaDex’s proprietary form of NR, Niagen®. “The results of this large human trial directly support the efficacy and safety of our NAD-boosting consumer product Tru Niagen,” says ChromaDex CEO Rob Fried.
ChromaDex Corp. (CDXC) announced today its flagship consumer product, Tru Niagen® (nicotinamide riboside) received the ‘Ingredient of the Year: Healthy Aging’ award at the NutraIngredients-USA Awards in New Orleans on June 3, 2019. “We are grateful to the judges for recognizing the quality of the science, the safe production processes, and the regulatory depth behind Tru Niagen in our efforts to support cellular health and healthy aging,” says ChromaDex CEO Rob Fried.
ChromaDex Corp. (CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 20th Annual B. Riley FBR Investor Conference at the Beverly Hilton Hotel in Beverly Hills, CA. The ChromaDex management team is scheduled to present on Wednesday, May 22, at 1:30 p.m. Pacific Time. ChromaDex management will also attend one-on-one meetings with institutional investors throughout the day. ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients.
ChromaDex (CDXC) delivered earnings and revenue surprises of 0.00% and 2.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Los Angeles-based company said it had a loss of 15 cents per share. Losses, adjusted for stock option expense, were 11 cents per share. The natural products company posted revenue of $10 million in ...
- First Quarter 2019 Net Revenues Increased by 53% to $10.0 Million - First Quarter 2019 Highlights vs. First Quarter 2018 Strong start to the year with $10.0 million of net.
ChromaDex Corp. (CDXC) announced today that it has entered into a note purchase agreement for the sale of $10.0 million of convertible notes in a private placement. The transaction was led by international strategic investors. The transaction is expected to close on or about May 17, 2019, subject to the satisfaction of customary closing conditions. The convertible notes will automatically convert into shares of ChromaDex common stock 45 days following the closing. The convertible notes will convert at $4.59 per share (market closing price on May 7, 2019), or if a common stock financing occurs in the 45 day period following the closing with a purchase price of less than $4.59 per share, at the price per share at which shares are issued in that financing.